News & Press

Press Releases

Keyword search
Abbisko Therapeutics Announces Dosing of First Patient in A Phase I Clinical Study of ABSK043 In Australia
Sep 03,2021
Abbisko Therapeutics Obtained Clinical Trial Approval for ABSK043 in Australia
Jul 12,2021
Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China
Jul 05,2021
Abbisko Therapeutics Announces Dosing of First Patient in A Phase Ib Clinical Study of ABSK011 In China
Jun 29,2021
Abbisko Therapeutics Announces the Appointment of Mr. Yongyi Li as General Counsel
Jun 04,2021
Abbisko Therapeutics Announces the Appointment of Ms. Jia Feng as Executive Director and Head of Human Resource
Jun 04,2021
Abbisko Therapeutics and AstraZeneca China Announce Strategic Partnership
May 25,2021
Burning Rock and Abbisko Therapeutics Announce Strategic Partnership on Co-development of Companion Diagnostics for ABSK091
Apr 29,2021
Abbisko Therapeutics Announces the Appointment of Dr. Zhen Zhang as CMC VP
Apr 19,2021
Abbisko Therapeutics Announces the Appointment of Dr. Jing Ji as Chief Medical Officer
Feb 18,2021
Abbisko Therapeutics Featured at the 39th Annual J.P. Morgan Healthcare Conference
Jan 19,2021
Abbisko Therapeutics Announces the Appointment of Dr. Xie Kewei as Chief Business Officer
Jan 12,2021
Abbisko Therapeutics Announces the Completion of $123 Million Series D Financing Led by The Carlyle Group
Jan 08,2021
Abbisko Therapeutics Announces the Appointment of Mr. Ye Lin as Chief Financial Officer
Nov 16,2020
Abbisko Therapeutics Obtained ABSK021 IND Approval in China
Oct 29,2020
Abbisko Therapeutics Obtained IND approval for Phase 1b/II Clinical Trial of Mavorixafor in Combination with Toripalimab in China
Sep 09,2020
Abbisko Therapeutics Announces $70M Series C Financing Led by Temasek
Mar 25,2020
Abbisko Therapeutics Announces Receiving of the IND Approval by the China NMPA for ABSK-011, A Novel FGFR4 Inhibitor
Mar 09,2020
Abbisko Therapeutics Announces the IND Approval of a Novel FGFR4 Inhibitor ABSK011 by the Taiwan FDA
Dec 06,2019
Abbisko Therapeutics Announces Initiation of Phase 1 Trial for ABSK021, its Selective CSF-1R Small Molecule Inhibitor
Aug 19,2019
X4 Pharmaceuticals and Abbisko Therapeutics Enter into Oncology Development and Commercialization Agreement for Mavorixafor in Greater China
Jul 17,2019
Abbisko Therapeutics Wins the Zhangjiang Science City Innovation & Progress Award for Outstanding Enterprises
Jan 18,2019
Abbisko Therapeutics is Awarded as One of the Most Promising Enterprises Founded by Foreign-educated Returnees
Dec 23,2018
Shanghai Mayor Ying Yong Presents Abbisko Therapeutics with “MNC’s R&D Centers” Certificate
Dec 07,2018
Dr. Hongping Yu Attends and Delivers a Speech at ACS Conference
Oct 28,2018
Abbisko Wins the Best Biomedical Investment Case Award in the Healthcare Investment Rankings 2018
Mar 30,2018
Dr. Yao-chang Xu Attends the Hong Kong Biotech Summit 2018
Mar 23,2018
Dr. Yao-chang Xu Presents at the BIO Asia International Conference
Mar 21,2018
Dr. Zhui Chen Attends China Healthcare Investment & Partnering Symposium 2018 on Invitation
Mar 16,2018
Dr. Yao-chang Xu Attends Zhangjiang League of Makers Health Industry Association’s Inauguration
Nov 20,2017
Dr. Yao-chang Xu Gives a Lecture at Peking University Clinical Research Institute
Apr 06,2017
Abbisko Completes Series A Round Financing of $ 28 Million
Feb 05,2017
Dr. Hongping Yu Attends a Teach-in at Nankai University on Invitation
Nov 24,2016
Dr. Yao-chang Xu Attends Bank of America Merrill Lynch China Annual Conference 2016 and Delivers a Speech
Nov 01,2016

Tel:(+86) 021-68912098

Copyright © 2021 All rights reserved:Abbisko Therapeautics     滬ICP備17056565號-1